PURE Bioscience Reports $2.20 Million Revenue with Net Loss of $2.40 Million for Fiscal Year Ending July 31, 2025

PURE Bioscience, Inc. reported a net revenue of $2.20 million for the fiscal year ending July 31, 2025, marking a 12.4% increase from $1.96 million in the previous year. Despite this growth in revenue, the company recorded a net loss of $2.40 million, slightly improved from a loss of $3.40 million in the prior fiscal year. The increase in revenue was primarily attributed to heightened sales across its end-user network, particularly within the food processing industry. However, the company continues to face significant financial challenges, including a cumulative net loss of approximately $139 million since its inception.

In terms of operational changes, PURE Bioscience has focused on expanding its product offerings, particularly its SDC-based products, which include PURE® Hard Surface and PURE Control®. These products are designed for food safety applications and have received regulatory approvals from the U.S. Environmental Protection Agency (EPA) and the U.S. Food and Drug Administration (FDA). The company has also engaged in strategic financing activities, raising $2 million through convertible promissory notes during the fiscal year, which has contributed to an increase in total liabilities to $6.17 million.

The company reported a gross margin of 59% for both fiscal years 2025 and 2024, indicating stable profitability on a per-product basis despite the overall net losses. Selling, general, and administrative expenses decreased to $3.26 million from $3.98 million, primarily due to reduced personnel and facility costs. Research and development expenses remained relatively stable, reflecting ongoing efforts to enhance product efficacy and compliance with regulatory standards.

As of July 31, 2025, PURE Bioscience had 11 full-time employees and 1 part-time employee, with no foreign sales reported during the fiscal year. The company is actively working to increase customer awareness and adoption of its products, which are critical for its growth strategy. The management has expressed concerns regarding its ability to continue as a going concern, emphasizing the need for additional capital to fund operations and support its business plan.

Looking ahead, PURE Bioscience aims to leverage its proprietary technology platform to develop new products and expand its market presence. The company is focused on enhancing its distribution network and exploring partnerships for international market entry. However, it acknowledges the competitive landscape and regulatory hurdles that may impact its growth trajectory. The management remains cautious about future financial performance, given the historical volatility in operating results and the ongoing need for capital to sustain operations.